Blood concentrations of Soliris (eculizumab) needed to fully suppress the immune complement cascade may be higher than previously thought in people with atypical hemolytic uremic syndrome (aHUS), according to a study from Spain. Most patients were found to have concentrations above estimated therapeutic levels in their bloodstream before…
News
A group of blood disorders called hypereosinophilia syndrome, known as HES, was suspected to be the trigger event that led to atypical hemolytic uremic syndrome (aHUS) in a woman in her late 30s, according to a new case study. HES is caused by an overload of eosinophils, a type…
With the theme “Capabilities and Possibilities,” this year’s aHUS Awareness Day — observed annually on Sep. 24 — seeks to highlight the achievements and aspirations of those living with atypical hemolytic uremic syndrome (aHUS). Overarchingly, the annual global event aims to call attention to aHUS itself, to educate…
Getting vaccinated against COVID-19 may protect people with atypical hemolytic uremic syndrome (aHUS) from the infection’s severe complications, without raising major safety issues, a small study finds. Receiving a double booster shot may be important to provide full protection, especially for transplant patients. “Our findings support the use of COVID-19…
Mutations in the THBD gene — previously suggested to predispose people to atypical hemolytic uremic syndrome (aHUS) — might not make any significant contribution to the disease’s development and its severity, according to a small Spanish study. The mutations were found in Spanish aHUS patients at similar frequencies to…
Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a kidney transplant, and they had better kidney function and a lower risk of transplant rejection, according to a meta-analysis of published studies. “This meta-analysis … demonstrated that [Soliris] produced meaningful…
The safety profile of Soliris (eculizumab) in real-world practice is similar to that reported in clinical trials, according to a large analysis of data from Japan. “This is the largest safety dataset on [Soliris] in Japan derived from more than 10 years of clinical experience,” the researchers wrote. “No…
Genetic screening of a large group of people suspected of having atypical hemolytic uremic syndrome (aHUS) detected very few gene variants likely to be associated with the condition, a study reported. Despite signs of aHUS, around two-thirds of those tested had no evidence of any known disease-causing variants. These…
Most patients and caregivers living with atypical hemolytic uremic syndrome (aHUS) prefer Ultomiris (ravulizumab-cwvz) over Soliris (eculizumab), a new study reports. The fact that Ultomiris is administered less often than Soliris was viewed as a key factor that separates the two medications and patients on Ultomiris were…
A case study of atypical hemolytic uremic syndrome (aHUS) caused by a new mutation in the DGKE gene highlights the disease’s early onset and severe difficult-to-treat course. The report, “Clinical features and management of atypical hemolytic uremic syndrome patient with DGKE gene variants: a case report,”…
Recent Posts
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent
- Early Soliris use boosts kidney recovery, cuts dialysis need in aHUS
- Dual therapy benefits man with aHUS, Castleman disease
- Pregnancy triggers aHUS with lung issues in woman: Case report